Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) has announced a strategic reconstitution of its Scientific Advisory Board (SAB) with the appointment of three distinguished experts in neurology, neuroimaging, and neurodegenerative diseases. This restructuring highlights the company's intensified focus on Alzheimer's disease within its clinical development pipeline, backed by encouraging data from studies involving its proprietary Deep Intracranial Frequency Stimulation (DIFS™) technology.
The newly appointed SAB members include Dr. Mingxiong Huang, a globally recognized expert in magnetoencephalography (MEG) and neuroimaging; Dr. David Owens, the company's Chief Medical Officer and a board-certified neuroradiologist; and Dr. Abe Scheer, who brings over four decades of experience in neurology and psychiatry. Together, they will guide Nexalin's scientific direction, clinical strategy, and biomarker-driven trial design for neurodegenerative and neuropsychiatric disorders.
"This enhanced advisory board reflects our sharpened focus on Alzheimer's disease, and the high-caliber expertise of Drs. Huang, Owens, and Scheer aligns with our expanding research agenda," said Mark White, CEO of Nexalin Technology. "Their combined contributions will be invaluable as we advance Nexalin's technology through clinical trials designed to address one of the greatest public health challenges of our time."
Innovative Neuromodulation Technology
Nexalin's approach centers on its Gen-2 SYNC and Gen-3 Halo™ headsets, which deliver DIFS™—a proprietary waveform capable of penetrating deep brain structures implicated in cognitive decline and mental illness. Recent published articles and preliminary data suggest that DIFS™ may promote neuroplasticity and functional recovery in brain regions associated with memory and executive function.
The technology represents a non-invasive, non-pharmacological approach to treating neurodegenerative conditions. Unlike traditional transcranial stimulation devices, Nexalin's technology is designed to reach deeper brain structures without causing discomfort or side effects. The Gen-2 15-milliamp neurostimulation device has already received regulatory approval in China, Brazil, and Oman.
Expert Leadership in Neuroscience
The reconstituted SAB brings together complementary expertise critical for advancing Nexalin's Alzheimer's program:
Dr. Mingxiong Huang contributes over 25 years of experience in developing and applying advanced imaging techniques to neurological and psychiatric disorders. As Professor of Radiology at the University of California, San Diego (UCSD) and Co-Director of the UCSD MEG Center, Dr. Huang has authored over 90 peer-reviewed publications and received the Distinguished Investigator Award from the Academy of Radiology Research. His expertise in brain imaging biomarkers directly supports Nexalin's data-driven approach to therapy development.
Dr. Abe Scheer, who previously served on the company's SAB, is board certified in both adult and pediatric neurology, as well as in brain injury medicine. With training and faculty positions at institutions including Columbia University, Cornell Medical College, and Georgetown University, Dr. Scheer brings extensive clinical experience and has been instrumental in launching neuromodulation therapy programs across the United States.
Dr. David Owens, serving as the Company's Chief Medical Officer, specializes in brain and spine imaging with more than 25 years of experience. His expertise includes advanced imaging techniques such as diffusion tensor imaging (DTI) and functional MRI, along with clinical research on transcranial stimulation therapies for various neurological and psychiatric conditions.
Clinical Development Plans
"This is a critical moment for innovation in Alzheimer's treatment," said Dr. Scheer. "Nexalin's technology represents a novel approach to brain modulation that could complement or even exceed the efficacy of traditional pharmacological therapies, particularly in the early stages of disease."
The company plans to initiate new Alzheimer's-focused clinical studies in the third quarter of 2025. These trials will incorporate cognitive testing, imaging biomarkers, and MEG-guided metrics to assess treatment efficacy and neural activation. The SAB will play a crucial role in optimizing trial designs and ensuring adherence to regulatory standards and scientific rigor.
"I am excited to work alongside Nexalin's leadership and fellow SAB members to help guide the next generation of non-invasive neuromodulation therapies," added Dr. Huang. "The intersection of neuroimaging, brain stimulation, and clinical science holds enormous potential for treating neurodegenerative disease."
Addressing an Urgent Medical Need
Alzheimer's disease affects millions worldwide, with limited effective treatment options currently available. The disease progressively destroys memory and cognitive function, eventually leading to complete dependence on caregivers. Current pharmacological approaches have shown modest benefits, often with significant side effects, highlighting the need for alternative therapeutic strategies.
Nexalin's non-invasive approach could potentially offer a complementary or alternative treatment option with a favorable safety profile. By targeting the underlying neural circuitry involved in cognitive decline, rather than focusing solely on amyloid plaques or tau tangles, the company's technology represents a distinct mechanistic approach to addressing Alzheimer's pathology.
The SAB reconstitution underscores Nexalin's evolution as a science-driven company committed to transforming mental health and neurodegenerative disease care through advanced bioelectronic medicine. With clinical trials planned for later this year, the company is positioning itself at the forefront of non-invasive neuromodulation for Alzheimer's disease.
